Skip to main content

Tracking Results of Ablations to Combat AF Registry Generation 2

Recruiting · NCT05111015

Conditions: Atrial Fibrillation

At a glance

Research payments reported, 2025
$624,877
U.S. investigators named
18
Sites paid
22
Planned or actual enrollment
10,000

About the trial

Sponsor
AtriCure, Inc.
Tested
Open Concomitant Surgical Ablation Procedures (device), Hybrid (Convergent) Ablation Procedures (device), AtriCure Hybrid Totally Thoracoscopic Ablation Procedures (device), AtriCure LAA Exclusion Procedures (device)
Dates
Started 2024-03-11; completion 2040-01
Results posted
Not yet

The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac ablation.

From ClinicalTrials.gov, last updated 2026-06-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Atricure, Inc. reported $624,877 in research payments for this study in 2025 (71 payments).

Products named: Isolator Surgical Ablation System, Atriclip Laa Exclusion System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.